Analyst firms · H.C. Wainwright · CBIO
H.C. Wainwright CBIO price target and rating history
Crescent Biopharma Inc. (CBIO) · Health Care
H.C. Wainwright rates Crescent Biopharma Inc. (CBIO) Buy with a $36 price target, as of its latest action on Oct 6, 2026. It has published 3 rating actions on CBIO since August 2025, including 1 upgrade and 1 downgrade. Across 3 firms with a CBIO price target in the last 12 months, the median target is $35. H.C. Wainwright's $36 is 3% above that.
- Current rating
- Buy
- Price target
- $36
- Median target, all firms
- $35
- Actions on CBIO
- 3
H.C. Wainwright price target on CBIO
Every H.C. Wainwright rating on CBIO
- Oct 6, 2026
- Jun 1, 2026
- Aug 11, 2025
How other firms rate CBIO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $36 | Oct 6, 2026 |
| Piper Sandler | Overweight | $35 | Jan 28, 2026 |
| Guggenheim | Buy | $35 | Jan 21, 2026 |
Questions about H.C. Wainwright and CBIO
- What is H.C. Wainwright's price target for CBIO?
- H.C. Wainwright's latest stated price target for Crescent Biopharma Inc. (CBIO) is $36, from its action on Oct 6, 2026.
- What is H.C. Wainwright's rating on CBIO?
- H.C. Wainwright rates CBIO Buy, a bullish rating, as of Oct 6, 2026.
- When did H.C. Wainwright last change its view on CBIO?
- On Oct 6, 2026, H.C. Wainwright upgrades to Buy from Neutral, price target $36.
- How does H.C. Wainwright's CBIO target compare with other analysts?
- Across 3 firms with a CBIO price target in the last 12 months, the median target is $35. H.C. Wainwright's $36 is 3% above that.
All H.C. Wainwright ratingsCBIO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.